Fig. 6 | Signal Transduction and Targeted Therapy

Fig. 6

From: Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response

Fig. 6

Anti-LAG-3 blockade effectively reduced tumour size in refractory EBV (+) GC. a A representative case of EBV (+) GC patient treated with MGD013. Flow chart showing each line of treatment options for the patient. b Representative mIHC staining in the EBV (+ ) GC sample before treatment of MGD013 for the following markers: CD8, GZMK, LAG-3 and DAPI. A dashed box represents the 4.5× enlarged area shown in the right panels with separate channels. White arrows point to cells positive for LAG-3, GZMK and CD8. Scale bar, 25 μm. c CT Imaging showing the response of this EBV (+) GC patient to MGD013 treatment. d A representative case of EBV (+) GC patient treated with KL-A289. Flow chart showing each line of treatment options for the patient. e Representative mIHC staining in the EBV (+) GC sample before treatment of KL-A289 for the following markers: CD8, GZMK, LAG-3 and DAPI. A dashed box represents the 4.5× enlarged area shown in the right panels with separate channels. White arrows point to cells positive for LAG-3, GZMK and CD8. Scale bar, 25 μm. f CT Imaging showing the response of this EBV (+) GC to KL-A289 treatment. g Dynamic changes of EBV DNA titre in this EBV (+) GC to KL-A289 treatment

Back to article page